Australia needs to align with other nations and implement sex and gender analysis
in health and medical research
Growing evidence from pre‐clinical1 and clinical research2 demonstrates that females/women
and males/men can differ significantly in susceptibility to common diseases and response
to treatment, including efficacy and adverse events.3 The mechanisms underlying sex
and gender differences will include epigenetic, genetic, endocrine, environmental,
social, economic and behavioural factors. Hence, ignoring sex and gender differences
across the research lifecycle — from grant submissions through to clinical translation
— has the potential to compromise the accuracy of science, result in detrimental health
outcomes, increase health costs, and have implications beyond health, including social
services and aged care.
Sex refers to the biological and physiological characteristics that define humans
(and other species) as male, female or intersex, based on chromosomal complement.
Gender references roles, behaviour and activities that a given society, at a given
time, considers appropriate for men, women and gender diverse persons. Disaggregation
of data by sex and/or gender enables the identification of differences between females/women
and males/men facilitating an understanding of the roles of both biological and sociocultural
factors in disease presentation and outcomes.
Knowledge of clinically significant sex and gender differences in screening, risk
factors, treatment and prognosis is emerging across a broad range of diseases, and
differences are identified for those conditions conferring the greatest health burden
in Australia and globally:4 cancer,2 cardiometabolic disease,5 mental illness,6 and
dementia.7
Historically and consistently across a broad‐range of health domains, data have been
collected from men and generalised to women.8 Failure to appreciate the differences
between and across the sex and gender spectrum risks compromising the quality of care
and increasing costs due to inappropriate allocation of resources.
As a consequence, growing numbers of countries, including the United States, Canada,
Ireland and Germany, have introduced policies and practices that require the integration
of sex and gender analyses in competitive research grants and publications in journals.9,
10 Whether similar policies and practices exist for Australian institutions has not
previously been documented.
In this article, we summarise the findings sourced from key documents that provide
an overview of the history and mechanisms in place in North America and Europe which
facilitate the integration of sex and gender into health research. We then provide
data on the policies and practices of Australian funding agencies and peer‐reviewed
journals relating to the collection, analysis and reporting of sex‐ and gender‐specific
health data. Finally, we make recommendations, launching a call to action to key stakeholders
to introduce such policies and practices in Australia.
The North American experience
In 1990, the National Institutes of Health (NIH) Office of Research on Women's Health
was founded under an edict from the US Congress. The Office of Research on Women's
Health was instrumental in the creation of the NIH Agenda for research on women's
health for the 21st century in 1999;11 it extended the scope of research policies
beyond involvement of women in studies to also include an understanding of sex differences.
In response, the Institute of Medicine established the Understanding the Biology of
Sex and Gender Differences committee, which produced the landmark report Exploring
the biological contributions to human health: does sex matter?
8
Policy change in the US further progressed when, in 2013, the US Food and Drug Administration
(FDA) issued a safety announcement that the recommended dose of zolpidem should be
halved for women,12 after research demonstrated that women had significantly higher
blood levels of zolpidem than men,13 causing impaired next‐day alertness and driving
safety concerns. In response to these findings, the FDA informed manufacturers to
reduce recommended doses accordingly for women.12 Until this point, women and men
had received the same dose. Canada followed the US dosage changes in January 2014.14
An FDA update in 2017 stated “The recommended initial dose of certain immediate‐release
zolpidem products … is 5 mg for women and either 5 mg or 10 mg for men. The recommended
initial dose of zolpidem extended‐release … is 6.25 mg for women and either 6.25 or
12.5 mg for men. If the lower doses (5 mg for immediate‐release, 6.25 mg for extended‐release)
are not effective, the dose can be increased to 10 mg for immediate‐release products
and 12.5 mg for zolpidem extended‐release”.12 The fact that this issue continues to
be debated15 strengthens our stance that sex and gender disaggregated analysis should
be included in all research analysis plans from the very beginning. The US zolpidem
recommendation has not been implemented in Australia.
Policies relating to the inclusion of females in research have now been extended beyond
clinical research to include cell lines and animal models.1, 10 In 2016, the NIH implemented
a policy that required sex be included as a biological variable in pre‐clinical research.10
Given the cost implications, the policy direction was accompanied by increased funding
to enable researchers to increase sample sizes to ensure they had sufficient power
to analyse sex separately.16
Three additional US organisations have been key contributors to this issue:
the Organization for the Study of Sex Differences (http://www.ossdweb.org), which
enhances knowledge of sex and gender analyses in health by facilitating interdisciplinary
communication and collaboration among scientists and clinicians;
the International Society of Gender Medicine (http://www.isogem.eu), which connects
national and professional societies dedicated to the study of sex‐ and gender‐specific
differences in health; and
Gendered Innovations in Science, Health and Medicine, Engineering, and Environment
(Stanford University and the European Commission; http://genderedinnovations.stanford.edu),
which provides tools and training to enable clinicians, researchers and policy makers
to understand and undertake sex and gender research.
In 2013, the Institute of Gender and Health (http://www.cihr-irsc.gc.ca/e/8673.html),
of the Canadian Institutes of Health Research, was established with the aim of integrating
sex and gender across the health research spectrum to assist development and implementation
of research findings on policies, services and systems that support better health
for all Canadians. The Canadian Institutes of Health Research requires all grant applicants
to respond to mandatory questions about sex and gender in research proposals.17 They
also provide online training modules on sex and gender in biomedical research for
scientists and peer reviewers, with the objectives of ensuring increased accuracy
of nomenclature used in sex and gender science, identifying methods to conduct sex
and gender science, and critically appraising the integration of sex and gender in
protocols and publications.18
The European experience
The European Association of Science Editors established a Gender Policy Committee
in 2012, with the aim “to advance gender‐ and sex‐sensitive reporting and communication
in science”19 and published the Sex and Gender Equity in Research (SAGER) guidelines
in 2016.20
The Lancet recently published a commentary on editorial policies with respect to sex
and gender analyses that proposed guidelines for medical journals, including accurate
use of sex and gender terms and reporting of sex, gender or both in study participants
and the sex of animals and cells.9
In Sweden, the Karolinska Institutet's Centre for Gender Medicine supports research
and education with a particular focus on how the promotion and implementation of sex
and gender analyses can drive innovation in health care (http://ki.se/en/research/centre-for-gender-medicine).
The League of European Research Universities published a paper in 2015 with 20 recommendations
about how universities can improve treatment of sex and gender in research and innovation,
stating that it must be better integrated into research funding, curriculum and clinical
practice.21
Finally, The European Commission has undertaken work in this field, including supporting
the development of the European Gender Medicine Network in 2013, which provides an
innovative framework for implementation of sex and gender in health research. In 2014,
the European Commission put in place a condition for Horizon 2020 funding that requires
applicants to “describe how sex and/or gender analysis is taken into account in the
project's content”.22
The Australian situation
A mixed methods analysis was undertaken by Carcel, Wainer, McKenzie, Webster and Norton
to determine whether funding agencies and peer‐reviewed journals in Australia have
policies on the collection, analysis and reporting of sex‐ and gender‐specific health
data. In addition, major medical granting agencies in Australia were identified through
the University of New South Wales (UNSW) Grants Management Office. The top ten peer‐reviewed
Australia‐based medical journals were identified through Journal Citation Reports.
Ethics approval was provided by the UNSW Ethics Committee (HC17866).
A web‐based search, performed between 1 and 5 December 2017 sought to identify the
existence of sex‐ and gender‐specific policies or practices of these agencies and
journals. Telephone interviews were undertaken between 5 January and 14 March 2018
with key informants from these organisations. The semi‐structured interviews covered
four main questions:
Does your organisation have a policy on sex and gender research integration?
Does your organisation have plans to develop one in the near future?
What in your view are barriers to changing current policies and practices?
What in your view are facilitators to changing current policies and practices?
Box 1 and Box 2 provide information on the 20 organisations that were included in
the study. As a result of the web‐based search, eight of the ten funding agencies
were identified as not having policies. The National Health and Medical Research Council
(NHMRC) and Diabetes Australia had policies on the collection, analysis or reporting
of sex‐ and gender‐specific health data. However, only the NHMRC specifically recommended
the analysis and reporting of sex‐ and gender‐specific data.
Box 1
Sex‐ and gender‐specific policies of the top ten granting agencies in Australia,*
according to a web‐based search in December 2017
Organisation
Presence of policy
Policy
National Health and Medical Research Council (NHMRC)
Yes
The NHMRC does not have a single policy document on sex and gender research integration.
However, advice is provided in several policy documents and in a number of different
sources:
Best practice methodology in the use of animals for scientific purposes (2017) (https://www.nhmrc.gov.au/guidelines-publications/ea20),
in specific terms under Section 3.1, “Quality of experimental design”, “the failure
to consider the use of both sexes in pre‐clinical studies involving animals (unless
there is a valid reason not to do so) can affect the validity of the outcomes from
such studies, which may then impact on the validity of their use as the basis for
clinical trials in humans”
The National Statement on Ethical Conduct in Human Research (2015) (https://www.nhmrc.gov.au/guidelines-publications/e72)
includes reference to principles of scientific merit, integrity and justice. A clinical
trial designed with scientific merit and integrity would ensure that the size and
profile of the sample to be recruited is adequate to answer the research question.
An appropriate balance of male and female participants may be necessary to ensure
the profile of participants is representative of the community in which the new drug
or device, for example, will be used. If one sex is to be excluded from a clinical
trial, a researcher would need to justify this to the reviewing Human Research Ethics
Committee
Policy accessed 19 December 2017
National Heart Foundation of Australia
No
No policy at this level at the time of the search
Cancer Council Australia
No
No policy at this level at the time of the search
Medical Research Future Fund
No
No policy at this level at the time of the search
New South Wales State Government (Office for Health and Medical Research)
No
No policy at this level at the time of the search
Victoria State Government (Cancer, Specialty Programs, Medical Research and International
Health, Health and Wellbeing Division)
No
No policy at this level at the time of the search
Diabetes Australia
Yes
Applicants must comply with the NHMRC's general principles (https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/3c9b4f5f-38c4-4cfb-a8f1-68689c906dae.pdf)
Policy accessed 19 December 2017
Leukaemia Foundation
No
No policy at this level at the time of the search
Australian Research Council
No
No policy at this level at the time of the search
Cancer Australia
No
No policy at this level at the time of the search
*
Identified through the University of New South Wales Grants Management Office.
Box 2
Sex‐ and gender‐specific policies of the top ten peer‐reviewed journals in Australia,*
according to a web‐based search in December 2017
Journal
Presence of policy
Policy
Journal of Gastroenterology and Hepatology
No
No policy at this level at the time of the search
The Medical Journal of Australia (MJA)
Yes
“The MJA follows the guidelines of the International Committee of Medical Journal
Editors [ICMJE] and the World Association of Medical Editors on publishing and editorial
matters, including peer review, conflict of interest and confidentiality” (https://www.mja.com.au/journal/mja-instructions-authors)
Policy accessed 19 December 2017
Clinical and Experimental Pharmacology and Physiology
No
No policy at this level at the time of the search
Immunology and Cell Biology
Yes
“Authors are encouraged to adhere to animal research reporting standards, for example
the ARRIVE reporting guidelines for reporting study design and statistical analysis”
(https://onlinelibrary.wiley.com/page/journal/14401711/homepage/ForAuthors.html#5)
Policy accessed 19 December 2017
Australian and New Zealand Journal of Psychiatry
Yes
“This Journal recommends that authors follow the Recommendations for the conduct,
reporting, editing, and publication of scholarly work in medical journals formulated
by the [ICMJE]” (https://au.sagepub.com/en-gb/oce/Journal/australian-new-zealand-journal-psychiatry#submission-guidelines)
Policy accessed 19 December 2017
Journal of Paediatrics and Child Health
No
No policy at this level at the time of the search
Australian and New Zealand Journal of Public Health
Yes
The journal endorses “the guidelines set out by the [ICMJE] in Uniform requirements
for manuscripts submitted to biomedical journals” (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1753-6405/homepage/ForAuthors.html)
Policy accessed 19 December 2017
Respirology
Yes
“Manuscripts should conform to the revised guidelines of the [ICMJE], published as
ICMJE Recommendations for the conduct, reporting, editing and publication of scholarly
work in medical journals” (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1440-1843/homepage/ForAuthors.html)
Policy accessed 19 December 2017
ANZ Journal of Surgery
Yes
“The journal complies with the [ICMJE's] Uniform requirements for manuscripts submitted
to biomedical journals: writing and editing for biomedical publication” updated February
2006 (http://www.ICMJE.org)” (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1445-2197/homepage/ForAuthors.html)
Policy accessed 19 December 2017
Clinical and Experimental Ophthalmology
No
No policy at this level at the time of the search
ARRIVE = Animal Research: Reporting of In Vivo Experiments.
*
Identified through Journal Citation Reports.
There was a mix of pre‐clinical and clinical peer‐reviewed journals identified through
InCites. Four of the ten journals did not have policies on the collection, analysis
and reporting of sex‐ and gender‐specific health data. Six of the journals (The Medical
Journal of Australia, Immunology and Cell Biology, the Australian and New Zealand
Journal of Psychiatry, the Australian and New Zealand Journal of Public Health, Respirology,
and the Australian and New Zealand Journal of Surgery) indicated they either followed
the reporting guidelines of the International Committee of Medical Journal Editors23
or the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.24
Of the 20 key informants invited to the interview, 12 agreed to participate. Among
the participants, seven were heads of funding agencies and five were editors of peer‐reviewed
journals. Five participants were women. The findings of the web‐based search were
confirmed as correct by the 12 key informants. Key informants from journals shared
that despite no publicly available policies on sex and gender health data, there were
internal rules that the editors, reviewers and authors followed. Lack of awareness
of the issue as well as the high cost of funding sex‐ and gender‐specific research
were perceived as barriers to changes in policy. The evidence of a need for policy
change and guidance from larger organisations was seen as a facilitator for change
within and across organisations. Overall, the majority of key informants were positive
about creating specific policies on the collection, analysis and reporting of sex‐
and gender‐specific health data. Most participants indicated that policies could be
developed within 2 years, and some said that a necessary factor in this would be involving
key individuals such as those from advisory and/or editorial committees.
Based on the positive responses to this Australian study, there is high expectation
that new policies, consistent with those adopted in many overseas countries, will
soon be effectively implemented in the Australian research funding environment. Further,
Australian peer‐reviewed journals can follow the proposed guidelines on reporting
on sex and gender in medical journals.20
Recommendations and a call to action to key stakeholders in Australia
All Australian Government departments and agencies are required to progressively align
their business practices with the Australian Government guidelines on the recognition
of sex and gender, which provide guidance about data collection, by 1 July 2016.25
The Standard for Sex and Gender Variables of the Australian Bureau of Statistics is
consistent with these guidelines.26 However, as identified in the study reported above,
Australian medical research has fallen behind North America and Europe in recognising
sex and gender as key determinants of health and their importance for health research
and improved health outcomes.
Multiple key stakeholders can act to raise awareness and facilitate the development
and implementation of sex and gender analysis in health and medical research, educate
researchers, scientists and clinicians, and drive change through funding and publication
requirements. We suggest a number of recommendations to these stakeholders and a call
for action (Box 3). In the absence of implementing these, there is a risk that Australia
will fail to keep pace with the rest of the world and, in turn, will become increasingly
less competitive when applying for funding from international bodies and will reduce
international partnership opportunities with overseas organisations. By implementing
these recommendations, Australia will align with other nations in improving health
research and practice to the benefit of the women, men, girls and boys of Australia.
This is not simply a women's or men's health issue, but an issue for all Australians.
Box 3
Recommendations for stakeholders
Stakeholder
Recommendation
Universities and other training institutions
Universities and other higher education training institutions, with the support of
multi‐institutional organisations (such as Medical Deans Australia and New Zealand),
should commit to developing systematic and nationally consistent curricula that acknowledge
and explore biological differences between males and females and the role of gender
and sociocultural factors in disease presentation and outcomes. This recommendation
has relevance across a range of faculties and disciplines, including medicine, public
health, pharmacy, nursing, allied health, and science
▶
There are multiple texts that support this initiative as well as example curricula
from Charité University Hospital in Berlin and Gendered Innovations at Stanford University18
University and other higher education ethics committees should ensure that implementation
of sex and gender analyses in research is managed as an ethical issue
Learned academies and professional societies
The Australian Academy of Health and Medical Sciences should encourage its members
to champion the integration of sex and gender analysis in research. Similarly, we
ask that the Australian Academy of Science creates a special interest group to ensure
that the following committees champion the integration of sex and gender analysis
in research: Mechanical and Engineering, Data in Science, Biomedical and Cellular
and Developmental Biology
The Council of Presidents of Medical Colleges should ensure that medical colleges
include evidenced‐based sex and gender integration in clinical guidelines, requirements
for funding for research, training and professional development
Australian‐based professional societies, such as the Australasian Epidemiological
Association, the Australian Society of Clinical and Experimental Pharmacology and
Toxicology, and many more, should promulgate the integration of sex and gender analysis
in research by developing policies, position papers, and sex‐ and gender‐specific
guidelines
Governments
The Therapeutic Goods Administration should require all new applications for registration
to address sex and gender differences
The Pharmaceutical Benefits Advisory Committee should consider how best the Pharmaceutical
Benefits Scheme might incorporate knowledge of sex and gender differences in facilitating
timely, reliable and affordable access to necessary medicines for Australians
Federal and state government health data bodies should develop a standard approach
to analysing sex and gender in all health reporting, ensuring that sex and gender
are treated as separate constructs when appropriate. Given its commitment to dealing
with this issue, the Australian Institute of Health and Welfare is well placed to
lead this initiative and provide policy direction for other health data groups and
agencies. We similarly ask that all federal and state health departments and agencies
align their data collection practices with the Australian Government guidelines on
the recognition of sex and gender and the Australian Bureau of Statistics Standard
for Sex and Gender Variables
The National Health and Medical Research Council (NHMRC) Australian Health Ethics
Committee should review content relating to sex and gender in the National Statement
on Ethical Conduct in Human Research and revise as required to ensure that the implementation
of sex and gender analyses in research is managed as an ethical issue
Health funding bodies including the Independent Hospital Pricing Authority and Medicare
should consider sex and gender analyses in cost‐weighting calculations
The Australian Commission on Safety and Quality in Health Care should undertake to
include integration of sex and gender data collection and analyses in guidelines for
Clinical Quality Registries and ensure adherence to practice according to clinical
guidelines, where sex and gender differences occur in accreditation standards
Medical and health research funders
The Medical Research Future Fund, the NHMRC, and other federal and state government
health funders, as well as the National Heart Foundation of Australia, Cancer Council
Australia, Diabetes Australia, and other health‐related, not‐for‐profit funders and
researchers should promulgate the development of policies and practices, requiring
consideration be given to the inclusion of sex and gender analysis, or demonstrate
why it is not required, and guidelines to address the implementation of sex‐ and gender‐specific
clinical care and health promotion and prevention
Funders should develop a funding pool to cover the extra costs associated with including
sex‐ and gender‐specific analyses and they should make funding available to train
researchers and clinicians in how to undertake research that includes comprehensive
sex and gender analyses
Peer‐reviewed journals
Australian‐based, peer‐reviewed journal editors should develop and monitor the implementation
of policies to ensure researchers include sex and gender in reporting of research.
We ask that they support the implementation of unified policies in the requirements
for the publication of sex and gender analyses and we call on them to challenge submitted
manuscripts that do not address inclusion of sex and gender analyses in their reporting
Industry
Health industry stakeholders, such as pharmaceutical companies and medical device
companies, should ensure that all new products are developed, consistent with US Food
and Drug Administration regulatory policies, requiring the involvement of both males
and females in clinical trials and the integration of sex and gender analyses
The Sex and Gender Sensitive Research Call to Action Group (article authors)
Zoe Wainer1
Cheryl Carcel2
Martha Hickey3
Londa Schiebinger4
Annette Schmiede5
Briar McKenzie2
Christine Jenkins2
Jacqui Webster2
Mark Woodward2,6
Angela Hehir7
Benjamin Solomon3
Caroline de Costa8
Caroline Lukaszyk2
Deborah J Colville9
Erika Dempsey2
Gavin M Wright1
Gita D Mishra10
Jane RW Fisher11
Jayashri Kulkarni11
Julie Anne Mitchell7
Katrina Hutchison12
Kelly Thompson2
Louisa Jorm13
Louise Chappell14
Maarinke van der Meulen2
Amanda Henry2,15
Michelle DiGiacomo16
Rachel Huxley2,17
Rebecca Ivers2,15
Sanne Peters2,6
Wendy A Rogers12
Xia Wang2
Robyn Norton2,6
1 University of Melbourne, St Vincent's Hospital, Melbourne, VIC.
2 George Institute for Global Health, University of New South Wales, Sydney, NSW.
3 University of Melbourne, Melbourne, VIC.
4 Gendered Innovations in Science, Health and Medicine, Engineering, and Environment,
Stanford University, Stanford, CA, USA.
5 University of Sydney, Sydney, NSW.
6 George Institute for Global Health, University of Oxford, Oxford, UK.
7 National Heart Foundation of Australia, Sydney, NSW.
8 James Cook University, Cairns, QLD.
9 Melbourne Health and Northern Health, University of Melbourne, Melbourne, VIC.
10 University of Queensland, Brisbane, QLD.
11 Monash University, Melbourne, VIC.
12 Macquarie University, Sydney, NSW.
13 Centre for Big Data Research in Health, University of New South Wales, Sydney,
NSW.
14 Australian Human Rights Institute, University of New South Wales, Sydney, NSW.
15 University of New South Wales, Sydney, NSW.
16 Centre for Improving Palliative, Aged, and Chronic Care through Clinical and Research
Translation, University of Technology Sydney, Sydney, NSW.
17 Deakin University, Melbourne, VIC.
Competing interests
No relevant disclosures.
Provenance
Not commissioned; externally peer reviewed.